CAPR News and Press, Capricor Therapeutics Inc. From 06/24/21

Marin Software Incorporated (MRIN) +63% on new InstaCart Ad Integration.India Globalization Capital (IGC) +22% on Alzheimer’s drug trial update.GTT Communications (GTT) +21%.Aravive, Inc. (ARAV) +20% on early-stage kidney cancer study data.Arcus Biosciences (RCUS) +19%&#...

Capricor Therapeutics (CAPR) announces $75M common stock offering.Company intends to use the net proceeds for research and development related to the company’s product candidates, manufacturing of the company’s products, working capital and general corporate purposes.Company has...

Gainers: Midatech Pharma (MTP) +33%.Cellect Biotechnology (APOP) +31%.iSun (ISUN) +23%.AGM Group (AGMH) +23%.Synaptogenix (SNPX) +21%9F (JFU) +18%.Capricor Therapeutics (CAPR) +15%.Clearside Biomedical (CLSD) +14%.Rezolute (RZLT) +14%.China Xiangtai Food (PLIN) +13%.Losers: ...

LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of...

LOS ANGELES, June 10, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that the compan...

-Capricor’s Findings Support Expansion Across Multiple Therapeutic Targets- -Conference will be held virtually: May 18 – May 21- LOS ANGELES, May 18, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development...

Capricor Therapeutics, Inc. (CAPR) Q1 2021 Earnings Conference Call May 13, 2021, 4:30 PM ET Company Participants AJ Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Officer Conference Call Participants Alan Leong - BioWatch News Presentation Operator Greetings. And welc...

Capricor Therapeutics (CAPR): Q1 GAAP EPS of -$0.23.Revenue of $0.04M (-78.9% Y/Y)Shares +3.2%.Press Release For further details see: Capricor Therapeutics reports Q1 results

-- -Requested Meeting with FDA to Discuss Next Steps in Development of CAP-1002 for Duchenne Muscular Dystrophy- -Data for Phase II INSPIRE Clinical Trial Expected in Third Quarter- -Plan to File IND for Multivalent Exosome-mRNA Vaccine for SARS-CoV-2 in Third Quarter- -To Hos...

--Conference Session: Therapeutic Applications of Extracellular Vesicles: From Diagnostics to Drug Delivery-- LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exos...